1 / 10

Detection is Better than Cure: Understanding the Various Factors Causing Anxiety Disorders and Depression

The global anxiety disorders and depression treatment market was valued at USD 22.5 billion in 2013 and is expected to reach USD 18.2 billion in 2020, at a CAGR of (1.25%) from 2014 to 2020.

kksingha
Télécharger la présentation

Detection is Better than Cure: Understanding the Various Factors Causing Anxiety Disorders and Depression

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Transparency Market Research Anxiety Disorders and Depression Treatment Market-Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 Published Date 26-Sep-2014 111 Page Report Request Sample Buy Now Press Release Anxiety Disorders and Depression Treatment Market to Exhibit 1.25% CAGR in View of Unimpressive Drug Pipeline:Transparency Market Research Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com

  2. Anxiety Disorder And Depression Market REPORT DESCRIPTION Anxiety Disorders and Depression Treatment Market-Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 Anxiety disorders and depression are common psychiatric disorders that affect a large number of people during their lifetime. This study provides the market analysis for the major drug classes used for the treatment of anxiety disorders and depression. The stakeholders of this report include established pharmaceutical companies as well as new entrants who wish to enter the market. Browse Full Report With TOC: http://www.transparencymarketresearch.com/anxiety-disorders-depression- treatments.html The market overview chapter, which has been provided in the study, analyzes the current market dynamics and other trends such as drivers, restraints, opportunities that would govern the present and future circumstances of the anxiety disorder and depression treatment market. Furthermore, Porter’s five forces analysis has been incorporated in this research to provide the competitive status of the anxiety disorders and depression treatment market; and market attractiveness analysis has been included to describe the market position across various geographies. Event impact analysis has been provided in this report for better understanding the significant events that have taken place in the past and are planned for the future and which might have a major impact on industry growth. Regulatory framework has also been discussed in this section to provide an overall idea about the regulatory scenario across the major geographies. Report Press Release: http://www.transparencymarketresearch.com/pressrelease/global-anxiety-disorders- depression-treatments.htm This research on anxiety disorders and depression treatment has been categorized based on various classes of drugs that are generally used for the treatment of these psychiatric conditions. Various drug classes considered while estimating the overall market are selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tetracyclic antidepressants (TeCAs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), benzodiazepines, beta-blockers, atypical antipsychotics and anticonvulsants. The market for these drug classes has been comprehensively analyzed based on the expiry, launch, sales revenue, efficacy and geographic presence of leading drugs in each of the classes mentioned above. Market revenue (USD million) for each of these drug classes has been provided in the research for the period 2012 to 2020 in terms of USD million, with CAGR for the forecast period 2014 to 2020, taking into account 2013 as the base year. In terms of geography, the global anxiety disorders and depression treatment market has been categorized into four major regions: North America, Europe, Asia Pacific and Rest of the World (RoW). In the geography section of the report, the market revenue (USD million) of various drug classes used for the treatment of anxiety disorders and depression for each of these geographic regions for 2012 and 2020 along with forecast period from 2014 to 2020 has been provided and explained in detail. Browse Article:http://www.transparencymarketresearch.com/article/anxiety-disorders-depression-treatments.htm 2 Transparency Market Research

  3. Anxiety Disorder And Depression Market The chapter on competitive landscape included in the report provides a detailed market share analysis of the major leading companies in the anxiety disorders and depression treatment market, in terms of percentage share for the year 2013. The detailed market share analysis of the industry participants involved in the market would help new organizations to identify the product portfolio of established global players and understand the business plans followed by key companies for sustaining in the market. Several pointers on strategic recommendations have also been provided for new industry participants as well as established organizations to help in securing a strong position in the global market and improve market share. Furthermore, the research comprises a chapter on pipeline analysis for this industry that includes sales forecast for recently launched drugs and potential drugs that are undergoing phase III clinical trials and are expected to be marketed during the forecast period. The report provides in-depth company profiles of major players in the anxiety disorders and depression treatment market based on a variety of characteristics such as company overview, financial overview, product portfolio, business strategies and recent developments. Major players profiled in this study include AstraZeneca plc, Eli Lilly and Company, Forest Laboratories, Inc., Johnson and Johnson, GlaxoSmithKline plc, H. Lundbeck A/S, Pfizer, Inc., Merck & Co., Inc. and Sanofi S.A. The global anxiety disorders and depression treatment market is segmented as follows: Anxiety Disorders and Depression Treatment Market, by Drug Class Selective Serotonin Reuptake Inhibitors (SSRIs) Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Atypical Antipsychotics Tricyclic Antidepressants (TCAs) Tetracyclic Antidepressants (TeCAs) Monoamine Oxidase inhibitors (MAOIs) Benzodiazepines Beta-Blockers Anticonvulsants Anxiety Disorders and Depression Treatment Market, by Geography North America Europe 3 Transparency Market Research

  4. Anxiety Disorder And Depression Market Asia-Pacific Rest of the World (RoW) Table Of Contents Chapter 1 Introduction 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.4 Assumptions Chapter 2 Executive Summary 2.1 Market Snapshot: Global Anxiety Disorders and Depression Treatment Market 2.2 Comparative Analysis: Global Anxiety Disorders and Depression Treatment Market, By Geography, 2013 and 2020 (Value %) Chapter 3 Global Anxiety Disorders and Depression Treatment Market Overview 3.1 Market Dynamics and Overview 3.2 Market Drivers 3.2.1 Rising geriatric population expected to boost market growth 3.2.2 Greater efficacy and reduced side effects of drugs in various classes likely to drive market growth 3.2.3 Escalating prevalence of depression and anxiety disorders likely to contribute to market growth 3.3 Market Restraints 3.3.1 Patent expirations of major drugs during the forecast period expected to impede market growth 3.3.2 Dry pipeline of novel drugs is hindering market growth 3.3.3 Drug resistant-mental disorders likely to challenge augmentation of the market 3.3.4 Increasing number of generic drug variants might negatively affect market growth 3.4 Market Opportunities 3.4.1 Improving distribution network in budding economies 4 Transparency Market Research

  5. Anxiety Disorder And Depression Market 3.4.2 Development of herbal remedies 3.5 Porter’s Five Forces Analysis 3.5.1 Bargaining Power of Suppliers 3.5.2 Bargaining Power of Buyers 3.5.3 Threat of Substitutes 3.5.4 Threat of New Entrants 3.5.5 Competitive Rivalry 3.6 Event Impact Analysis 3.7 Market Attractiveness Analysis: Global Anxiety Disorder and Depression Treatment Market, by Geography 3.8 Regulatory Framework 3.9 Market Share Analysis: Global Anxiety Disorders and Depression Treatment Market, by Key Players, 2013 (Value %) Chapter 4 Global Anxiety Disorders and Depression Treatment Market, by Drug Class 4.1 Overview 4.1.1 Global Anxiety Disorder and Depression Treatment Market Revenue, by Condition, 2012 – 2020 (USD Million) 4.1.2 Global Anxiety Disorders Treatment Market Revenue, by Drug Class, 2012 – 2020 (USD Million) 4.1.3 Global Depression Treatment Market Revenue, by Drug Class, 2012 – 2020 (USD Million) 4.2 Selective Serotonin Reuptake Inhibitors (SSRIs) 4.2.1 Global SSRIs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million) 4.2.2 Global SSRIs Market Revenue, by Depression, 2012 – 2020 (USD Million) 4.3 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 4.3.1 Global SNRIs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million) 4.3.2 Global SNRIs Market Revenue, by Depression, 2012 – 2020 (USD Million) 4.4 Atypical Antipsychotics 4.4.1 Global Atypical Antipsychotics Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million) 4.4.2 Global Atypical Antipsychotics Market Revenue, by Depression, 2012 – 2020 (USD Million) 4.5 Tricyclic Antidepressants (TCAs) 4.5.1 Global TCAs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million) 5 Transparency Market Research

  6. Anxiety Disorder And Depression Market 4.5.2 Global TCAs Market Revenue, by Depression, 2012 – 2020 (USD Million) 4.6 Tetracyclic Antidepressants (TeCAs) 4.6.1 Global TeCAs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million) 4.6.2 Global TeCAs Market Revenue, by Depression, 2012 – 2020 (USD Million) 4.7 Monoamine Oxidase inhibitors (MAOIs) 4.7.1 Global MAOIs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million) 4.7.1.1 Global MAOIs Market Revenue, by Depression, 2012 – 2020 (USD Million) 4.8 Benzodiazepines 4.8.1 Global Benzodiazepines Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million) 4.8.2 Global Benzodiazepines Market Revenue, by Depression, 2012 – 2020 (USD Million) 4.9 Beta-Blockers 4.9.1 Global Beta-Blockers Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million) 4.10 Anticonvulsants 4.10.1 Global Anticonvulsants Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million) Chapter 5 Global Anxiety Disorders and Depression Treatment Market, Pipeline Analysis 5.1 Overview 5.2 Brintellix (Vortioxetine - Lu AA21004) 5.2.1 Global Brintellix Market Revenue, 2014 – 2020 (USD Million) 5.3 Brexpiprazole (OPC-34712) 5.3.1 Global Brexipiprazole Market Revenue, 2016 – 2020 (USD Million) 5.4 ALKS-5461 5.4.1 Global ALKS-5461 Market Revenue, 2016 – 2020 (USD Million) Chapter 6 Global Anxiety Disorders and Depression Treatment Market, by Geography 6.1 Overview 6.1.1 Global Anxiety Disorders and Depression Treatment Market Revenue, by Geography, 2012 – 2020 (USD Million) 6.1.2 Global Anxiety Disorders Treatment Market Revenue, by Geography, 2012 – 2020 (USD Million) 6 Transparency Market Research

  7. Anxiety Disorder And Depression Market 6.2 North America 6.2.1 North America Anxiety Disorders and Depression Treatment Market Revenue, 2012 - 2020 (USD Million) 6.3 Europe 6.3.1 Europe Anxiety Disorders and Depression Treatment Market Revenue, 2012 - 2020 (USD Million) 6.4 Asia Pacific 6.4.1 Asia Pacific Anxiety Disorders and Depression Treatment Market Revenue, 2012 - 2020 (USD Million) 6.5 Rest of the World (RoW) 6.5.1 RoW Anxiety Disorders and Depression Treatment Market Revenue, 2012 - 2020 (USD Million) Chapter 7 Recommendations 7.1 Emphasis on Developing Novel and Combination Products 7.2 Targeting Emerging Economies (China, Singapore, Brazil, Dubai, India, South Africa and Mexico) for Marketing Generic Pharmaceuticals 7.3 Strategic Partnership with Biopharmaceutical Organizations Chapter 8 Company Profiles 8.1 AstraZeneca PLC 8.1.1 Company Overview 8.1.2 Financial Overview 8.1.3 Product Portfolio 8.1.4 Business Strategies 8.1.5 Recent Developments 8.2 Eli Lilly and Company 8.2.1 Company Overview 8.2.2 Financial Overview 8.2.3 Product Portfolio 8.2.4 Business Strategies 8.2.5 Recent Developments 8.3 Forest Laboratories, Inc. 7 Transparency Market Research

  8. Anxiety Disorder And Depression Market 8.3.1 Company Overview 8.3.2 Financial Overview 8.3.3 Product Portfolio 8.3.4 Business Strategies 8.3.5 Recent Developments 8.4 GlaxoSmithKline plc 8.4.1 Company Overview 8.4.2 Financial Overview 8.4.3 Product Portfolio 8.4.4 Business Strategies 8.4.5 Recent Developments 8.5 H. Lundbeck A/S 8.5.1 Company Overview 8.5.2 Financial Overview 8.5.3 Product Portfolio 8.5.4 Business Strategies 8.5.5 Recent Developments 8.6 Johnson & Johnson 8.6.1 Company Overview 8.6.2 Financial Overview 8.6.3 Product Portfolio 8.6.4 Business Strategies 8.6.5 Recent Developments 8.7 Merck & Co., Inc. 8.7.1 Company Overview 8.7.2 Financial Overview 8.7.3 Product Portfolio 8.7.4 Business Strategies 8 Transparency Market Research

  9. Anxiety Disorder And Depression Market 8.7.5 Recent Developments 8.8 Pfizer, Inc. 8.8.1 Company Overview 8.8.2 Financial Overview 8.8.3 Product Portfolio 8.8.4 Business Strategies 8.8.5 Recent Developments 8.9 Sanofi-Aventis 8.9.1 Company Overview 8.9.2 Financial Overview 8.9.3 Product Portfolio 8.9.4 Business Strategies 8.9.5 Recent Developments Request For Sample Report:- http://www.transparencymarketresearch.com/sample/sample.php? flag=S&rep_id=1199 Browse All Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html About Us Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge. Contact Transparency Market Research 9 Transparency Market Research

  10. Anxiety Disorder And Depression Market 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/ Browse The Market Research Blog : https://herepharmablog.wordpress.com 10 Transparency Market Research

More Related